Skip to main content

Table 2 Treatment profiles and corresponding predicted choice probabilities

From: Physicians’ preferences for bone metastases treatments in France, Germany and the United Kingdom

Attribute Characteristics similar to denosumab Characteristics similar to zoledronic acid Characteristics similar to clodronate Characteristics similar to pamidronate
Time until first SRE, months 27.7 19.5 15–20 (assume 17.5) 10.9
Time until worsening of pain, months 5.9 5.6 3.0 0.03–several (assume 3.0)
Risk of ONJ each year, % 1.8 1.3 Yes, but value not stated (assume 1.0) Yes, but value not stated (assume 1.0)
Risk of renal impairment each year, % 0 9.3 Yes, but value not stated (assume 5.0) 8.1
Mode of administration Injection every 4 weeks 15-min infusion every 4 weeks Daily oral tablet 120-min infusion every 4 weeks
Predicted choice probabilities; country, mean (95% CI)     
France 90.4 (84.1, 94.2) 3.9 (2.0, 7.1) 5.3 (3.1, 9.0) 0.4 (0.1, 1.0)
Germany 93.5 (88.9, 96.3) 3.6 (1.9, 6.7) 2.6 (1.5, 4.5) 0.2 (0.1, 0.6)
UK 90.3 (84.8, 94.0) 3.8 (2.1, 6.6) 5.6 (3.3, 9.0) 0.3 (0.1, 0.7)
  1. Values for pain worsening for denosumab and zoledronic acid were based on von Moos et al. 2013 [25], and for clodronate on Jagdev et al. 2001 [36]. The value for time until complication of bone metastases for clodronate was based on Kristensen et al. 1999 [37]. All other values were derived from the prescribing information for denosumab, zoledronic acid, clodronate and pamidronate [18,19,20, 33,34,35], with assumptions made, as stated, where definitive published values were absent
  2. CI, confidence interval; ONJ, osteonecrosis of the jaw; SRE, skeletal-related event; UK, United Kingdom
\